What medications are used to treat emphysema?

Lung emphysema—more accurately termed *emphysema*, a key component of chronic obstructive pulmonary disease (COPD)—is a progressive, irreversible structural lung disorder characterized by destruction of alveolar walls, loss of elastic recoil, and permanent enlargement of airspaces distal to the terminal bronchioles. Because emphysema reflects permanent anatomical damage, no medication can reverse or cure it. Treatment focuses on slowing disease progression, reducing symptom burden, preventing exacerbations, and improving quality of life.

First-line pharmacologic therapy centers on inhaled bronchodilators. Long-acting beta₂-agonists (LABAs; e.g., salmeterol, formoterol, indacaterol) and long-acting muscarinic antagonists (LAMAs; e.g., tiotropium, umeclidinium, glycopyrronium) are used either alone or in combination—often as dual-bronchodilator inhalers—to improve airflow, reduce dynamic hyperinflation, and alleviate dyspnea. For patients with frequent exacerbations and elevated blood eosinophil counts (≥300/μL), inhaled corticosteroids (ICS) may be added to LABA/LAMA regimens (e.g., fluticasone/vilanterol, budesonide/glycopyrronium/formoterol), though ICS use requires careful risk–benefit assessment due to increased risks of pneumonia and osteoporosis.

Nonpharmacologic interventions are equally critical: smoking cessation remains the single most effective intervention to slow decline in lung function; pulmonary rehabilitation improves exercise tolerance and reduces hospitalizations; annual influenza and pneumococcal vaccinations lower infection-related exacerbation risk; and long-term oxygen therapy is indicated for patients with severe resting hypoxemia (PaO₂ ≤55 mmHg or SpO₂ ≤88%). In select advanced cases, surgical or bronchoscopic lung volume reduction may be considered to improve mechanics and symptoms.

Importantly, treatment must be individualized based on symptom severity (assessed via tools like the mMRC or CAT questionnaire), exacerbation history, spirometric findings (particularly post-bronchodilator FEV₁), comorbidities, and patient preferences. Regular follow-up and inhaler technique assessment are essential to optimize outcomes.